Asymptomatic Left Ventricular Systolic Dysfunction (Stage B Heart Failure) and Response to Chronic Protein Therapy With SQ BNP

被引：0
|
作者：
McKie, Paul M. [1 ]
Schirger, John A. [1 ]
Cataliotti, Alessandro [1 ]
Simari, Robert A. [1 ]
Redfield, Margaret M. [1 ]
Burnett, John C. [1 ]
Chen, Horng C. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
CIRCULATION | 2013年 / 128卷 / 22期
关键词：
Heart failure; Natriuretic peptide; Pharmacology; Kidney; Prevention;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
14335
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Stage B heart failure - Management of asymptomatic left ventricular systolic dysfunction
    Goldberg, Lee R.
    Jessup, Mariell
    CIRCULATION, 2006, 113 (24) : 2851 - 2860
  • [2] Novel Protein Therapeutics for Human Preclinical Diastolic Dysfunction (Stage B Heart Failure): Chronic SQ BNP Administration
    Wan, Siu-Hin
    McKie, Paul M.
    Schirger, John A.
    Cataliotti, Alessandro
    Simari, Robert D.
    Redfield, Margaret M.
    Burnett, John C.
    Chen, Horng H.
    JOURNAL OF CARDIAC FAILURE, 2013, 19 (08) : S65 - S65
  • [3] Diabetes, left ventricular systolic dysfunction, and chronic heart failure
    MacDonald, Michael R.
    Petrie, Mark C.
    Hawkins, Nathaniel M.
    Petrie, John R.
    Fisher, Miles
    McKelvie, Robert
    Aguilar, David
    Krum, Henry
    McMurray, John J. V.
    EUROPEAN HEART JOURNAL, 2008, 29 (10) : 1224 - 1240
  • [4] Left atrial remodelling contributes to the progression of asymptomatic left ventricular systolic dysfunction to chronic symptomatic heart failure
    Karayannis, George
    Kitsios, George
    Kotidis, Haralambos
    Triposkiadis, Filippos
    HEART FAILURE REVIEWS, 2008, 13 (01) : 91 - 98
  • [5] Left atrial remodelling contributes to the progression of asymptomatic left ventricular systolic dysfunction to chronic symptomatic heart failure
    George Karayannis
    George Kitsios
    Haralambos Kotidis
    Filippos Triposkiadis
    Heart Failure Reviews, 2008, 13 : 91 - 98
  • [6] The treatment of chronic heart failure due to left ventricular systolic dysfunction
    Gardner, RS
    McDonagh, TA
    CLINICAL MEDICINE, 2004, 4 (01) : 18 - 22
  • [7] Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction
    Rorth, Rasmus
    Jhund, Pardeep S.
    Mogensen, Ulrik M.
    Kristensen, Soren L.
    Petrie, Mark C.
    Kober, Lars
    McMurray, John J. V.
    DIABETES CARE, 2018, 41 (06) : 1285 - 1291
  • [8] Benefits of Natriuretic Peptide Guided Heart Failure Therapy for Patients With Chronic Left Ventricular Systolic Dysfunction: Primary Results of the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study
    Januzzi, James
    Rehman, Shafiq U.
    Mohammed, Asim A.
    Bhardwaj, Anju
    Barajas, Linda
    Barajas, Justine
    Kim, Han-Na
    Baggish, Aaron L.
    Weiner, Rory B.
    Chen-Tournoux, Annabel A.
    Marshall, Jane E.
    Moore, Stephanie A.
    Carlson, William
    Lewis, Gregory D.
    Shin, Jordan
    Sullivan, Dorothy
    Parks, Kimberly
    Wang, Thomas
    Gregory, Shawn A.
    Uthamalingam, Shanmugam
    Semigran, Marc J.
    CIRCULATION, 2010, 122 (21) : 2221 - 2221
  • [9] The prevalence of heart failure and asymptomatic left ventricular systolic dysfunction in a typical regional pacemaker population
    Thackray, SDR
    Witte, KKA
    Nikitin, NP
    Clark, AL
    Kaye, GC
    Cleland, JGF
    EUROPEAN HEART JOURNAL, 2003, 24 (12) : 1143 - 1152
  • [10] Angiotensin converting enzyme inhibition in asymptomatic left ventricular systolic dysfunction and early heart failure
    Konstam, MA
    EUROPEAN HEART JOURNAL, 1995, 16 : 59 - 64
12345